GlassScriptPhysician profile
Jordan M Roussel
NPI 1205290350
$4,890.70
in general payments reported to CMS, 2019-2025
31 companies · $1,272 in 2025
The $1,272 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.76 · 2020: $168 · 2021: $577 · 2022: $694 · 2023: $877 · 2024: $1,261 · 2025: $1,272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,409.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,921.61 | 2020-2025 | Skyrizi, Rinvoq, Viberzi |
| Janssen Biotech, INC. | $376.10 | 2023-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $352.53 | 2020-2025 | Entyvio, Gattex, Eohilia |
| Gilead Sciences, INC. | $335.78 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $260.87 | 2021-2022 | |
| Celgene Corporation | $201.27 | 2023-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $162.24 | 2023-2025 | Ocaliva |
| Ardelyx, INC. | $150.41 | 2023-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $144.49 | 2022-2024 | Linzess |
| Ipsen Biopharmaceuticals, INC | $134.31 | 2024-2025 | Iqirvo, Bylvay |
| Lilly USA, LLC | $110.47 | 2024-2025 | Omvoh |
| Boston Scientific Corporation | $105.08 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $89.65 | 2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $74.65 | 2023-2024 | Voquezna |
| Aimmune Therapeutics, INC. | $47.87 | 2024-2025 | Zenpep |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $47.77 | 2021 | |
| Celltrion USA INC. | $40.75 | 2024 | Vegzelma |
| Daiichi Sankyo INC. | $40.62 | 2022-2024 | Injectafer |
| Qol Medical, LLC | $36.47 | 2023 | Sucraid |
| Evoke Pharma, INC. | $35.28 | 2023 | Gimoti |
| Pfizer INC. | $35.25 | 2019-2025 | |
| Capsovision, INC. | $30.05 | 2023 | Capsocam Plus |
| Braintree Laboratories, INC. | $29.39 | 2020-2021 | |
| Orphalan INC | $24.86 | 2025 | Cuvrior |
| Pharmacosmos Therapeutics INC. | $24.52 | 2023 | Monoferric |
| Erbe USA INC | $15.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.15 | 2023 | Cyltezo |
| Mallinckrodt Hospital Products INC. | $13.81 | 2023 | Terlivaz |
| Covidien LP | $12.22 | 2019 | |
| Medtronic, INC. | $11.67 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $11.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Roussel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.